In 2016, the then US President Barack Obama announced the Cancer Moonshot with a view
to making 10 years' worth of progress in cancer prevention, diagnosis and treatment in only …

Background In the phase III CheckMate 227 study, first-line nivolumab+ ipilimumab
significantly prolonged progression-free survival (co-primary end-point) versus …

Aim: A systematic review and network meta-analysis were conducted to evaluate the efficacy
of pembrolizumab+ pemetrexed+ platinum relative to other regimens in metastatic …

PURPOSE In the phase 3 KEYNOTE-407 study, the addition of pembrolizumab to
carboplatin-paclitaxel/nab-paclitaxel significantly improved overall survival, progression-free …

Introduction In the phase II/III KEYNOTE-010 study (ClinicalTrials. gov, NCT01905657),
pembrolizumab significantly prolonged overall survival over docetaxel in patients with …

Introduction Immunotherapy and chemoimmunotherapy clinical trials for metastatic non–
small-cell lung cancer (mNSCLC) have generally excluded patients with poor performance …

The development of PD-1, PD-L1 and CTLA-4 immune checkpoint inhibitors (CPI) has
revolutionised the treatment of advanced non-small cell lung cancer (NSCLC). The potential …

Purpose Lung cancer is one of the most common types of cancer, resulting in approximately
1.8 million deaths worldwide. Immunotherapy using checkpoint inhibitors has become …

The advent of PD-(L) 1 and CTLA-4 immune check point inhibitors (CPIs) has dramatically
changed the treatment landscape of advanced non-small-cell lung cancer (NSCLC). For up …

The rapidly expanding repertoire of immune checkpoint inhibitors (ICIs) now includes two
agents, pembrolizumab and atezolizumab, approved for first‐line treatment of advanced non …